Foresee Pharmaceuticals Co Ltd - ESG Rating & Company Profile powered by AI
Full ESG assessment of Foresee Pharmaceuticals Co Ltd are reached by signing up for free. Other companies in the scoring peer group for Foresee Pharmaceuticals Co Ltd are shown below. This page includes a Q&A table for Foresee Pharmaceuticals Co Ltd.
Foresee Pharmaceuticals Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.2; made up of an environmental score of 2.0, social score of 0.0 and governance score of 1.6.
1.2
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1755 | TRACON Pharmaceuticals Inc | 1.3 | Low |
1755 | Trimurthi Ltd | 1.3 | Low |
1779 | Foresee Pharmaceuticals Co Ltd | 1.2 | Low |
1779 | Cell Biotech Co Ltd | 1.2 | Low |
1779 | Aurisco Pharmaceutical Co Ltd | 1.2 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Foresee Pharmaceuticals Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Foresee Pharmaceuticals Co Ltd disclose current and historical energy intensity?
Does Foresee Pharmaceuticals Co Ltd report the average age of the workforce?
Does Foresee Pharmaceuticals Co Ltd reference operational or capital allocation in relation to climate change?
Does Foresee Pharmaceuticals Co Ltd disclose its ethnicity pay gap?
Does Foresee Pharmaceuticals Co Ltd disclose cybersecurity risks?
Does Foresee Pharmaceuticals Co Ltd offer flexible work?
Does Foresee Pharmaceuticals Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Foresee Pharmaceuticals Co Ltd disclose the number of employees in R&D functions?
Does Foresee Pharmaceuticals Co Ltd conduct supply chain audits?
Does Foresee Pharmaceuticals Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Foresee Pharmaceuticals Co Ltd conduct 360 degree staff reviews?
Does Foresee Pharmaceuticals Co Ltd disclose the individual responsible for D&I?
Does Foresee Pharmaceuticals Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Foresee Pharmaceuticals Co Ltd disclose current and / or historical scope 2 emissions?
Does Foresee Pharmaceuticals Co Ltd disclose water use targets?
Does Foresee Pharmaceuticals Co Ltd have careers partnerships with academic institutions?
Did Foresee Pharmaceuticals Co Ltd have a product recall in the last two years?
Does Foresee Pharmaceuticals Co Ltd disclose incidents of discrimination?
Does Foresee Pharmaceuticals Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has Foresee Pharmaceuticals Co Ltd issued a profit warning in the past 24 months?
Does Foresee Pharmaceuticals Co Ltd disclose parental leave metrics?
Does Foresee Pharmaceuticals Co Ltd disclose climate scenario or pathway analysis?
Does Foresee Pharmaceuticals Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Foresee Pharmaceuticals Co Ltd disclose the pay ratio of women to men?
Does Foresee Pharmaceuticals Co Ltd support suppliers with sustainability related research and development?
Does Foresee Pharmaceuticals Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Foresee Pharmaceuticals Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Foresee Pharmaceuticals Co Ltd involved in embryonic stem cell research?
Does Foresee Pharmaceuticals Co Ltd disclose GHG and Air Emissions intensity?
Does Foresee Pharmaceuticals Co Ltd disclose its waste policy?
Does Foresee Pharmaceuticals Co Ltd report according to TCFD requirements?
Does Foresee Pharmaceuticals Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Foresee Pharmaceuticals Co Ltd disclose energy use targets?
Does Foresee Pharmaceuticals Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Foresee Pharmaceuticals Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Foresee Pharmaceuticals Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Foresee Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. The company was incorporated in 2013 and is based in Taipei, Taiwan.